ProstaLund
22% sales growth in the quarter
MAR
- Fourth quarter in a row with growth
1 Januay-31 March
- Net sales reached SEK 5,6 (4,6) million
- Loss after taxes SEK -3,2 (-2,1) million
- Earnings per share were SEK -0,06 SEK (-0,04)
- Cash and equivalents were 6,3 (7,9) million
Significant events during period
- CE-mark for the new platform Eagle obtained
- Patent that include the Schelin Catheter is approved
- An agreement with a new clinic in Stockholm was signed
- An agreement with a new clinic in Karlshamn was signed
- Agreement with SLG Kalmar is signed with an order value of SEK 2,4 million
Significant events after the end of the period
- Distribution agreement for Poland was signed
- Schelin Catheter® approved for sale in the province of Hainan in China
- The board decided on May 17th 2023 to carry out a rights issue of approx. 40 MSEK before issue costs
Key figures | ||||
(SEK MILLION) | jan-mar 2023 | jan-mar 2022 | jan-mar 2021 | jan-mar 2020 |
Net sales | 5,6 | 4,6 | 5,3 | 4,6 |
Gross margin, % | 68 | 81 | 83 | 72 |
Operating profit/loss | -3,2 | -2,1 | -1,2 | -1,6 |
Cash flow from operating activities | -5,5 | -5,1 | -2,2 | 1,4 |
Average number of employees | 9 | 7 | 7 | 5 |
”The first quarter of the year was characterized by the same intensity as 2022. We began the year with continued growth and reported the highest turnover ever during a quarter”
Johan Wennerholm
CEO, ProstaLund AB (publ)
Please see attached PDF for full report.
Datum | 2023-05-17, kl 08:15 |
Källa | MFN |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!